CHO PHARMA, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.2 TWD | -0.36% |
|
+0.91% | -20.35% |
| Mar. 20 | CHO Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | CHO Pharma, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
ETFs positioned on CHO Pharma, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | +1.11% | - |
CHO PHARMA INC. is principally engaged in the development of new drugs related to sugar molecules. The companyâs technology and development can be divided into eight categories according to its patent features, including homogeneous antibody drugs, monoclonal antibodies of cancers and immune-related diseases, carbohydrate-related vaccines and drugs, anti-influenza drugs, the development and application of Saccharin tablets, the development and application of sugar probes, the synthesis identification development and application of sugar molecular, as well as the derivative patents of innovation development plans.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -20.35% | 362M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.35B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 6586 Stock
- Funds and ETFs CHO Pharma, Inc.
